Literature DB >> 9478946

Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors.

P Gaudin1, J J Maoret, A Couvineau, C Rouyer-Fessard, M Laburthe.   

Abstract

The human vasoactive intestinal peptide (VIP) 1 receptor belongs to the new class II subfamily of G protein-coupled receptors. Specific change by mutagenesis of a strictly conserved histidine into arginine at position 178 of the human VIP1 receptor resulted in its constitutive activation with respect to cAMP production. Transfection of the H178R mutant into COS cells resulted in a 3.5-fold increase in the cAMP level as compared with cells transfected with the wild type receptor or the vector alone. This increase was proportional to the amount of transfected cDNA. The H178R mutant exhibited an otherwise normal cAMP response to VIP as well as a dissociation constant similar to that of the wild type receptor. Other mutants at position 178 such as H178K, H178A, and H178D were not constitutively activated. They were otherwise expressed at the cell surface of transfected nonpermeabilized cells. Double mutants were then constructed in which the H178R mutation was associated with a point mutation in the the N-terminal extracellular domain that totally abolished VIP binding or VIP-stimulated cAMP production, i.e. E36A or D68A. The corresponding double mutants H178R/E36A and H178R/D68A were no longer constitutively activated. A control double mutant (H178R/D132A) with an unaltered dissociation constant for VIP and cAMP response to VIP was still constitutively activated. Our findings demonstrate that constitutive activation of the VIP1 receptor by mutation of His178 into R requires the functional integrity of the N-terminal extracellular VIP binding domain. They might provide interesting generalities about the activation process of G protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9478946     DOI: 10.1074/jbc.273.9.4990

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations.

Authors:  Denise Wootten; John Simms; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

Review 2.  Conformational switches in the VPAC(1) receptor.

Authors:  Ingrid Langer
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  An angiotensin II type 1 receptor activation switch patch revealed through evolutionary trace analysis.

Authors:  Marie Mi Bonde; Rong Yao; Jian-Nong Ma; Srinivasan Madabushi; Stig Haunsø; Ethan S Burstein; Jennifer L Whistler; Søren P Sheikh; Olivier Lichtarge; Jakob Lerche Hansen
Journal:  Biochem Pharmacol       Date:  2010-03-21       Impact factor: 5.858

4.  Constitutive activation of the neurotensin receptor 1 by mutation of Phe(358) in Helix seven.

Authors:  Séverine Barroso; Françoise Richard; Delphine Nicolas-Ethève; Patrick Kitabgi; Catherine Labbé-Jullié
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.

Authors:  A Couvineau; J J Maoret; C Rouyer-Fessard; I Carrero; M Laburthe
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

6.  The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.

Authors:  Emilie Ceraudo; Samuel Murail; Yossan-Var Tan; Jean-Jacques Lacapère; Jean-Michel Neumann; Alain Couvineau; Marc Laburthe
Journal:  Mol Endocrinol       Date:  2007-09-20

7.  The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.

Authors:  Emilie Ceraudo; Yossan-Var Tan; Pascal Nicole; Alain Couvineau; Marc Laburthe
Journal:  J Mol Neurosci       Date:  2008-07-03       Impact factor: 3.444

Review 8.  The EGF-TM7 family: a postgenomic view.

Authors:  Mark J Kwakkenbos; Else N Kop; Martin Stacey; Mourad Matmati; Siamon Gordon; Hsi-Hsien Lin; Jörg Hamann
Journal:  Immunogenetics       Date:  2003-11-27       Impact factor: 2.846

Review 9.  Family-B G-protein-coupled receptors.

Authors:  A J Harmar
Journal:  Genome Biol       Date:  2001-11-23       Impact factor: 13.583

10.  Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.

Authors:  Ingrid Langer
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-30       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.